Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MEDVidi vs Mevo Health

MEDVidi
Graded #384

Lower grade

vs+2.200000000000003
Mevo Health
Graded #327

Higher grade

The verdict

Mevo Health takes it — 60.2/100 to 58/100.

Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMevo Health +11
45
56
Dose & formulationMevo Health +30
53
83
Clinical oversightMEDVidi +10
77
67
Labs & monitoringMEDVidi +10
62
52
FulfillmentMEDVidi +2
59
57
Contract termsMEDVidi +35
55
20
MEDVidi · left barMevo Health · right bar

The numbers

MetricMEDVidiMevo Health
WeighScore58/10060.2/100
GradeCC
Scorecard rank#384#327
SemaglutideNot disclosed$199/mo (all doses, compounded)
TirzepatideNot disclosed$259/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
MEDVidi

Graded #384 · C

Strengths

  • Licensed providers can prescribe brand-name Zepbound and Wegovy
  • Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
  • Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

Where it loses points

  • Consult-fee model: medication is not included and its cost is separate
  • No medication pricing is published
  • State list is shown as a map rather than enumerated
Mevo Health

Graded #327 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard